Seeking Alpha HealthcareOriginal article
Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy
Phase 2negativeNegative
AI Analysis
Summary
Acadia Pharmaceuticals experienced a mid-stage trial setback for its Alzheimer's psychosis therapy, resulting in a significant stock price decline.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Not Met
Importance:7/10
Sentiment:
-0.80
clinical_trialsetbackAlzheimer'spsychosismid-stage
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on September 24, 2026 12:03 PM